AAP
RNAC icon

Arax Advisory Partners’s Cartesian Therapeutics RNAC Stock Holding History

Arax Advisory Partners’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$67.5K Buy
6,475
+6,456
+33,979% +$47.8K ﹤0.01% 3030
2026
Q1 		$117 Buy
+19
New +$135 ﹤0.01% 3598
2025
Q4 		– Sell
-111
Closed -$1.14K – 4457
2025
Q3 		$1.14K Buy
+111
New +$1.25K ﹤0.01% 3233
2024
Q4 		– Sell
-12
Closed -$194 – 2694
2024
Q3 		$194 Hold
12
– – ﹤0.01% 2514
2024
Q2 		$325 Buy
+12
New +$286 ﹤0.01% 2390

Other funds holding RNAC

Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Arax Advisory Partners's RNAC Position: Q2 2026 in Review

Arax Advisory Partners increased its Cartesian Therapeutics (RNAC) stake by 33,979% in Q2 2026, buying an estimated $47.8K and bringing the position to 6,475 shares worth $67.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3030.

Arax Advisory Partners first reported a position in RNAC in Q2 2024 and has held it in 5 quarters since. 95 funds tracked by Wall St. Rank hold RNAC as of Q2 2026.

  • Arax Advisory Partners held 6,475 shares of Cartesian Therapeutics worth $67.5K as of Q2 2026.
  • Arax Advisory Partners bought 6,456 Cartesian Therapeutics shares in Q2 2026, an estimated $47.8K.
  • Cartesian Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #3030 holding.
  • Arax Advisory Partners first reported a position in Cartesian Therapeutics in Q2 2024 and has held it in 5 quarters since.
  • 95 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.